FDA Approves MYCOPHENOLATE MOFETIL — CONCORD BIOTECH LIMITED

Concord Biotech Limited won approval for its ANDA212087 on July 31, 2020, for the oral product Mycophenolate Mofetil, indicating the company is positioned to enter the generic market for this immunosuppressant. The approval signals a potential increase in competition for the branded drug, which could lead to greater market accessibility and pressure on pricing within the organ transplant sector.